These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 8320247

  • 1. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR.
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [Abstract] [Full Text] [Related]

  • 2. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT, Umen AJ, Kasiske B, Goerdt P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV.
    Transplantation; 1995 Feb 15; 59(3):371-6. PubMed ID: 7871567
    [Abstract] [Full Text] [Related]

  • 5. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun 15; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 6. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM.
    Transplantation; 1993 Jan 15; 55(1):110-6. PubMed ID: 8380508
    [Abstract] [Full Text] [Related]

  • 7. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM.
    Transplantation; 1989 Apr 15; 47(4):599-605. PubMed ID: 2523099
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD, Book BK, Milgrom ML, Leapman SB, Petersen B, Filo RS.
    Surgery; 1994 Oct 15; 116(4):811-8. PubMed ID: 7940183
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP, Kormos RL, Armitage JM, Dummer JS, Hardesty RL.
    J Heart Transplant; 1990 Oct 15; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [Abstract] [Full Text] [Related]

  • 12. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ, Jordan SC, Nathan SD, Kass RM, Koerner SK.
    Chest; 1996 Apr 15; 109(4):870-3. PubMed ID: 8635362
    [Abstract] [Full Text] [Related]

  • 13. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC, Powderly WG, Storch GA, Miller SB, Dunkel JD, Woodward RS, Spitznagel E, Hanto DW, Dunagan WC.
    Am J Kidney Dis; 1993 Feb 15; 21(2):196-201. PubMed ID: 8381577
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A, Gallino A, Schneider J, Bauer EP, Carrel T, Pasic M, von Segesser LK, Turina MI.
    J Heart Lung Transplant; 1992 Feb 15; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
    Copeland JG, Icenogle TB, Williams RJ, Rosado LJ, Butman SM, Vasu MA, Sethi GK, McDonald AN, Klees E, Rhenman MJ.
    J Thorac Cardiovasc Surg; 1990 May 15; 99(5):852-60. PubMed ID: 2329823
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.